Mylan says FDA warning for Agila site won't hit financial assumptions
This article was originally published in Scrip
Mylan does not expect the US FDA's warning letter against Agila Specialties' steriles site to have a material impact on its deal with the Indian firm, with no change anticipated in the targeted timelines for the closure of the acquisition. "Based on what we know today, we continue to expect to close the Agila acquisition in Q4 2013 and do not expect that the matter will have a material impact on our financial assumptions with regard to our combined business," Mylan told Scrip.
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.